StockNews.AI
REGN
New York Post
92 days

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

1. Regeneron acquires 23andMe for $256 million out of bankruptcy. 2. The deal includes access to over 15 million genetic samples. 3. Regeneron commits to consumer privacy amid data concerns. 4. 23andMe's valuation dropped from $6 billion to $50 million. 5. Regulatory approvals are required before closure in Q3 2025.

M&A
+3.67%Current Return
VS
-0.22%S&P 500
$593.0305/19 12:51 PM EDTEvent Start
$614.7905/20 07:11 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Acquisition strengthens Regeneron's data capabilities for future research, similar to past biotech acquisitions that boosted market confidence.

How important is it?

Data acquisition can drive innovation and competitive advantage in personalized medicine, impacting REGN's future financial performance significantly.

Why Long Term?

Long-term growth expected from enhanced genetic data utilization in drug development; similar long-term benefits were seen in companies like Illumina.

Related Companies

ILMNBMYGILDAMGN

Related News